COMIRNATY

Medical Information
United Kingdom
 

This site is intended for UK healthcare professionals and the information provided is not intended as medical advice.

Responsibility for patient care resides with the healthcare professional.

This content is intended for UK healthcare professionals. Would you like to proceed?

March 5, 2021

This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and the Summary of Product Characteristics will be updated as necessary.

Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)